Delving into the Latest Updates on Alisertib with Synapse

The goal of this clinical trial is to determine how well people tolerate treatment with alisertib at different doses when it is used together with paclitaxel to treat people with SCLC. The main question it aims to answer is:
* What percentage of side effects, both mild and serious, do participants experience when being treated with alisertib and paclitaxel based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v.5.0)?
The study will consist of different groups, called cohorts, in which alisertib will be studied at increasing doses. Participants in the first group, Cohort 1, will take 30 mg of alisertib by mouth 2 times a day. The dose will increase by 10 mg 2 times a day for each new cohort of participants joining the study. Side effects will be checked during the study, and the decision to increase the dose of alisertib will be based on the specific side effects experienced during the first 21 days of treatment for each cohort.
Participants will:
* take alisertib by mouth on their own 2 times a day from Day 1 through Day 7 of each 21-day cycle and will be given paclitaxel intravenously at a dose of 60 mg/m2 on Day 1 and Day 8 of each 21-day cycle.
* be given a preventive treatment to increase their body defenses, called granulocyte-colony stimulating factor (G-CSF). Study staff will give G-CSF after the last dose of alisertib or paclitaxel of each 21-day cycle in which alisertib was given.
* provide blood samples to evaluate the different levels of alisertib in the blood at different times. Blood samples will be collected on Days 1 and 7 of the first and second 21-day cycles of treatment.
* be treated with alisertib and paclitaxel until death, worsening of the disease, unacceptable toxicity, unwillingness to continue participating in the trial, or other criteria that requires participants to stop treatment and participation in the study.
* be contacted every 8 weeks after stopping alisertib and paclitaxel treatment as part of a specific study phase called the long-term follow-up period. This will last until death, unwillingness to continue participating in the trial, or until the end of the study.

Start Date30 Sep 2026

Sponsor / Collaborator

Puma Biotechnology, Inc.

NCT07706179

/ Not yet recruitingPhase 2IIT

Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer: A Biomarker-Driven Pilot Clinical Trial

The goal of this clinical trial is to learn if alisertib in addition to usual care works to treat HR+/HER2+ breast cancer. The main questions it aims to answer are:
* Does alisertib stop the communication between HR and HER2?
* Are there genetic markers that predict how well someone's cancer will respond to alisertib?
Participants will receive alisertib in addition to their usual care.

Start Date01 Aug 2026

Sponsor / Collaborator

University of Wisconsin-Madison

NCT06369285

/ RecruitingPhase 2

A Phase 2 Study of Alisertib in Combination With Endocrine Therapy in Patients With HR+, HER2-negative Recurrent or Metastatic Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy. Participants randomized prior to Amendment 4 are randomized 1:1:1 to Arm 1, Arm 2 or Arm 3. Participants randomized under Amendment 4 will be randomized 1:1 to Arm 1 or Arm 2.

Start Date19 Nov 2024

Sponsor / Collaborator

Puma Biotechnology, Inc.

100 Clinical Results associated with Alisertib

Login to view more data

100 Translational Medicine associated with Alisertib

Login to view more data

100 Patents (Medical) associated with Alisertib

Login to view more data

561

Literatures (Medical) associated with Alisertib

02 Jul 2026·MOLECULAR CANCER THERAPEUTICS

Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor

Article

Author: Nurmemmedov, Elmar ; Bitler, Benjamin G. ; Elder, Alan M. ; Petkov, Alexander ; Reigan, Philip ; Woodruff, Elizabeth R. ; Brubaker, Lindsay W. ; Eisenmesser, Elan ; Yamamoto, Tomomi M. ; Iwanaga, Ritsuko

Abstract:

Chromobox 2 (CBX2), a subunit of polycomb repressor complex 1 (PRC1), is expressed in high-grade serous carcinoma (HGSC). CBX2-inhibitory peptide (CBX2i) has demonstrated efficacy in a syngeneic mouse model but has limitations. We sought to identify an alternative approach to CBX2 inhibition. A computational-based molecular docking screen was performed using the Selleckchem Bioactive Library to identify inhibitors of CBX2. A similarity screen of top hits against the bound conformation of CBX2i pharmacophore model was performed in parallel. A series of in vitro validation studies evaluated the effect of alisertib on proliferation, a CBX2 target gene, and stemness. CBX2-knockdown cell lines and a syngeneic murine model were utilized to evaluate alisertib response in the context of CBX2 loss. Cell target engagement assay was performed. PRC1 activity was measured by H2AK119ub levels. Immune profiling of treated tumors defined the immune microenvironment. The computational-based screen identified 10 candidate compounds. In vitro validation narrowed compounds of interest to raltitrexed, alisertib, GTX-007, LY315920, and PD0325901. Ultralow dilution assay demonstrated a dramatic decrease in spheroid formation with alisertib, an aurora A kinase (AURKA) inhibitor. Good structural overlap was observed between CBX2i and alisertib. Cell target engagement assay confirmed alisertib selectivity for both AURKA and CBX2. Loss of CBX2 attenuated alisertib efficacy in vitro and in vivo. Treatment with alisertib leads to a decrease in H2AK119ub and shift in the immune tumor microenvironment. Alisertib efficacy in HGSC is dependent on functional CBX2, and cell target engagement confirms selectivity for CBX2, supporting that alisertib activity involves CBX2 inhibition.

01 Jul 2026·PHYTOMEDICINE

Tongguanteng injection induces cell cycle arrest and drives ferroptosis through AURKA/KEAP1/NRF2 axis in breast cancer

Article

Author: Liang, Hanlu ; Guo, Cheng ; Chen, Junjun ; Shi, Meizhi ; Ding, Qixuan ; Hu, Yujie ; Zhou, Yangyun ; Han, Yonglong ; Zhang, Xiangqi ; Zhao, Shuai ; Zhang, Jingxian ; Chen, Jiayi ; Xu, Lingyan ; Yang, Jiao

BACKGROUND:

Tongguanteng Injection (TGT), derived from the stems of Marsdenia tenacissima, has been demonstrated to exert anti-tumor effects. Aurora Kinase A (AURKA) is a key regulator of cell cycle progression and has become a promising target for breast cancer treatment. However, the role of AURKA in ferroptosis is unclear, particularly regarding its contribution to the therapeutic effect of TGT in breast cancer.

METHODS:

The chemical components of TGT were analyzed by Ultra-high performance liquid chromatography coupled with hybrid quadrupole-orbitrap high resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS). The anti-breast cancer effect of TGT were detected in vitro and in vivo. RNA-seq analysis were used to identify the targets of TGT treatment. Subsequently, flow cytometry, RT-PCR, western blot, Co-IP, immunofluorescence and immunohistochemistry were employed to elucidate the regulatory mechanisms of TGT on ferroptosis and cell cycle. Concurrently, ferroptosis and cell cycle associated pathways were investigated in the plasmids and siRNAs transfected cells. Furthermore, tumor bearing mouse model was established by 4T1 cells stably transduced with lentivirus for further validating the findings.

RESULTS:

A total of 136 compounds were identified from TGT. The study demonstrates that TGT exerts an anti-breast cancer effect by inducing G2/M phase arrest and ferroptosis, evidenced by downregulation of CDK1 and Cyclin B, as well as increased Fe²⁺ accumulation, glutathione (GSH) depletion, and elevated lipid peroxidation. RNA-seq analysis revealed that AURKA was significantly downregulated and identified as a key target of TGT treatment. Mechanistically, TGT disrupts the AURKA-Kelch-like ECH-associated protein 1 (KEAP1) interaction, leading to nuclear factor E2-related factor 2 (NRF2) nuclear translocation and subsequent heme oxygenase 1 (HO-1)-mediated ferroptosis in vitro. Knockdown of AURKA or treatment with its inhibitor alisertib both induce G2/M phase arrest and ferroptosis, while AURKA overexpression reverses the effects of TGT and accelerates tumor progression. Combining TGT with docetaxel enhances ferroptosis sensitivity and amplifies the regulatory effect of AURKA on cell cycle and ferroptosis. Consistent with in vitro results, TGT significantly inhibited tumor growth, arrested cell cycle and promoted ferroptosis in 4T1-AURKA^LV cell bearing mice.

CONCLUSION:

These findings propose that TGT targets AURKA/KEAP1/NRF2 axis to exert anti-breast cancer effect, and AURKA inhibition represents a potential strategy for breast cancer treatment through inducing cell cycle arrest and driving ferroptosis.

29 Apr 2026·NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Alisertib exerts AURKA-independent antitumor activity in colon cancer by modulating immune-related pathways.

Article

Author: Hui, Kaiyuan ; Zhang, Xingyu ; Liu, Bin ; Jiang, Xiaodong ; Gao, Qi ; Yu, Zien ; Li, Luyao ; Zou, Xun ; Feng, Yiwen ; Shen, Xiaozhu

Colon cancer (CC) ranks as the third most common cancer and the second leading cause of cancer-related death worldwide. Despite significant advances in treatment and early intervention, the precise mechanisms of action for many targeted therapies remain to be fully elucidated. This study aimed to investigate the potential off-target effects of the AURKA inhibitor Alisertib in colon cancer. Transcriptomic analysis revealed a striking divergence between AURKA silencing and Alisertib treatment: AURKA knockdown predominantly affected cell cycle-related pathways, whereas Alisertib significantly modulated immune-related pathways. This functional heterogeneity at the transcriptomic level suggests that Alisertib's mechanism of action is not solely dependent on AURKA inhibition. Through bioinformatics prediction and experimental validation, we further identified ZAP70 as a leading candidate mediator of Alisertib's effects. Crucially, a series of in vitro and in vivo experiments demonstrated that Alisertib's ability to suppress malignant phenotypes and tumor growth in colon cancer cells was maintained irrespective of AURKA overexpression, confirming its AURKA-independent activity. Collectively, our findings systematically reveal that Alisertib exerts significant AURKA-independent antitumor effects in colon cancer, likely mediated through alternative mechanisms such as the regulation of ZAP70 and associated immune pathways. This study provides a novel perspective on the pharmacological action of Alisertib and its clinical application.

84

News (Medical) associated with Alisertib

24 Jul 2026

·www.biospace.com

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, August 6, 2026, following the release of its second quarter 2026 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at . A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX ® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX ® is a registered trademark of Puma Biotechnology, Inc. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA ® -Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA ® -Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. ALISCA ® is a registered trademark of Puma Biotechnology, Inc. Further information about Puma Biotechnology may be found at . Contacts Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500 info@pumabiotechnology.com ir@pumabiotechnology.com David Schull, Russo Partners, +1 212 845 4200 david.schull@russopartnersllc.com

Drug ApprovalLicense out/inPhase 2Phase 1

02 Jul 2026

·www.biospace.com

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - July 2, 2026

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma common stock to four new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, July 1, 2026, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4). About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc. In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA®-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA®-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. Contacts Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500 info@pumabiotechnology.com ir@pumabiotechnology.com

Drug ApprovalLicense out/inPhase 2

04 Jun 2026

·www.biospace.com

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - June 3, 2026

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 7,000 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, June 1, 2026, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4). About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc. In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. Contacts Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500 info@pumabiotechnology.com ir@pumabiotechnology.com

Drug ApprovalLicense out/inPhase 2

100 Deals associated with Alisertib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10085	Alisertib	-	DB05220

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peripheral T-cell lymphoma unspecified refractory	Phase 3	United States	Millennium Pharmaceuticals, Inc.	11 Jun 2012
Peripheral T-cell lymphoma unspecified refractory	Phase 3	Australia	Millennium Pharmaceuticals, Inc.	11 Jun 2012
Peripheral T-cell lymphoma unspecified refractory	Phase 3	Austria	Millennium Pharmaceuticals, Inc.	11 Jun 2012
Peripheral T-cell lymphoma unspecified refractory	Phase 3	Belarus	Millennium Pharmaceuticals, Inc.	11 Jun 2012
Peripheral T-cell lymphoma unspecified refractory	Phase 3	Belgium	Millennium Pharmaceuticals, Inc.	11 Jun 2012
Peripheral T-cell lymphoma unspecified refractory	Phase 3	Brazil	Millennium Pharmaceuticals, Inc.	11 Jun 2012
Peripheral T-cell lymphoma unspecified refractory	Phase 3	Bulgaria	Millennium Pharmaceuticals, Inc.	11 Jun 2012
Peripheral T-cell lymphoma unspecified refractory	Phase 3	Canada	Millennium Pharmaceuticals, Inc.	11 Jun 2012
Peripheral T-cell lymphoma unspecified refractory	Phase 3	Chile	Millennium Pharmaceuticals, Inc.	11 Jun 2012
Peripheral T-cell lymphoma unspecified refractory	Phase 3	Czechia	Millennium Pharmaceuticals, Inc.	11 Jun 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SABCS2025	Phase 1/2	ER-positive/HER2-negative Breast Cancer ER+/HER2-	126	Alisertib monotherapy	ikixjjtewo(dhcyvsfdjx) = hematologic AEs (neutropenia, leukopenia, and anemia), and fatigue. mwzkutxfwd (zroggoiwvi )	Positive	10 Dec 2025
				Alisertib ± fulvestrant
NCT06369285 (ALISCA-Breast1, ASCO2025)	Phase 2	Hormone receptor positive HER2 negative breast cancer RB1 \| MYC \| TP53 ... View more	-	Alisertib 30 mg + Endocrine Therapy	xsyigpytru(wpjamihjtr) = dtzxazrrts itquftentm (xaddfgjtzs ) View more	Positive	30 May 2025
				Alisertib 40 mg + Endocrine Therapy	xsyigpytru(wpjamihjtr) = twhqpklaow itquftentm (xaddfgjtzs ) View more
NCT04555837 (CTgov)	Phase 1/2	Squamous cell carcinoma of head and neck metastatic \| Squamous Cell Carcinoma of Head and Neck \| Malignant Solid Neoplasm	24	Alisertib+Pembrolizumab (Phase I)	vsawwgeepq = pzfjftaigs jonungoorl (xaiixvajmj, twdodlghga - xvduxsrnll) View more	-	16 Dec 2024
				Alisertib+Pembrolizumab (Phase II)	wwdrhedkcl = kzgsggqsgt kpbvxzmzch (nmhspgnfql, wjgkzhlftt - jshbnyvbtz) View more
NCT02860000 (TBCRC041, CTgov)	Phase 2	Locally advanced breast cancer \| Metastatic breast cancer \| Hormone refractory breast cancer ... View more	96	Laboratory Biomarker Analysis+Alisertib (Arm I (Alisertib))	zlxvruqizv(gesjeurfoq) = lpimpqechp aqparfmsyv (wjtweedfvq, qrjwgojyov - rtjkolhcbm) View more	-	18 Oct 2024
				Laboratory Biomarker Analysis+Alisertib+fulvestrant (Arm II (Alisertib, Fulvestrant))	zlxvruqizv(gesjeurfoq) = hkwyctyqiu aqparfmsyv (wjtweedfvq, fwqmkpqmaw - gwzzyarhbq) View more
NCT02187991 (CTgov)	Phase 2	Metastatic breast cancer	169	Paclitaxel (ER+/HER2- Paclitaxel Alone)	krcdyzuitd(syfofgypju) = kmbsxhiyxw wpfujxojli (rtenmyenaq, svwszezjwn - hbgmpowzue) View more	-	09 Oct 2024
				Alisertib+Paclitaxel (ER+/HER2- Paclitaxel Plus Alisertib)	krcdyzuitd(syfofgypju) = hifyqjwsez wpfujxojli (rtenmyenaq, wsspqbuqkd - ipdhjymokr) View more
NCT04085315 (phase I/Ib study, ASCO2024) Manual	Phase 1	EGFR Mutation Lung Cancer EGFR	21	alisertib+osimertinib	qamrovurmi(wonhdpmhky) = neutropenia (42.9%), anemia (42.9%), and diarrhea (38.1%) brftnmkdbm (edluokagku )	Positive	24 May 2024
NCT02860000 (TBCRC041, ASCO2024)	Phase 2	Metastatic breast cancer ESR1 \| PIK3CAmutation \| AKT1 ... View more	91	Alisertib + Fulvestrant	ycbgfinzun(tndjzbyzyu): HR = 1.8 (95% CI, 1.1 - 2.9), P-Value = 0.014	Positive	24 May 2024
				Alisertib
NCT02187991 (ASCO2023) Manual	Phase 2	Metastatic Triple-Negative Breast Carcinoma \| Hormone receptor positive HER2 negative breast cancer HR Positive \| PR Negative \| ER Negative \| ... View more	96	alisertib (A) combined with paclitaxel (P) or P alone	sxxpmdnckf(rfcsyhuslb) = hdayzirvpq nyvbgoqaog (zgohzejhnj )	Positive	31 May 2023
NCT02860000 (Pubmed)	Phase 2	Advanced breast cancer CDK 4/6i	91	Alisertib	vnncjgobqj(hlaufqjfug) = doqtpcfccl ovlegvqmnr (mxbjxvjixk, 29.0% - 54.5%) View more	-	09 Mar 2023
				Alisertib + Fulvestrant	vnncjgobqj(hlaufqjfug) = tlvodfdkby ovlegvqmnr (mxbjxvjixk, 18.0% - 42.0%) View more
NCT02293005 (CTgov)	Phase 2	Unresectable Pleural Malignant Mesothelioma \| Mesothelioma, Malignant \| Lung Cancer	28	Alisertib	tvbdweszdo = wkwinbbuez vzkarldrao (eiphmxgzfz, szpyaiuxmi - ihmmnlxbvo) View more	-	04 Oct 2022